This Article Full Text (PDF) Other Versions of this Article: CVI.00343-07v1 15/5/817    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Liao, J. B. Articles by DiMaio, D. PubMed PubMed Citation Articles by Liao, J. B. Articles by DiMaio, D.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00343-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Single-Dose Therapeutic Vaccination of Mice with Vesicular Stomatitis Virus Expressing Human Papillomavirus Type 16 E7 Protein

Department of Obstetrics, Gynecology, and Reproductive Sciences; Investigative Medicine Program; Microbiology Graduate Program; Department of Pathology; Departments of Genetics, Molecular Biophysics and Biochemistry, and Therapeutic Radiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510

^* To whom correspondence should be addressed. Email: daniel.dimaio{at}yale.edu.

	Abstract

We are developing recombinant attenuated vesicular stomatitis virus (VSV) as a vaccine vector to generate humoral- and cell-mediated immune responses. Here, we explore the use of VSV vaccines for cancer immunotherapy. Immunotherapy targeting high-risk human papillomavirus (HPV) lesions has the potential to benefit HPV-infected individuals and cervical cancer patients by generating cytotoxic T cells that kill tumor cells that express viral antigens. A single dose of VSV expressing the HPV16 E7 oncogene was used for therapeutic vaccination of mice bearing TC-1 syngeneic tumors which express HPV16 E7. HPV16 E7-specific T-cells were generated and displayed cytotoxic activity against the tumor cells. By 14 days post-vaccination, average tumor volumes were 10-fold less in the vaccinated group compared to mice that received the empty vector VSV, and regression of pre-existing tumors occurred in some cases. This anti-tumor effect was CD8 T-cell dependent. Our results demonstrate anti-tumor responses to HPV16 E7 and suggest that recombinant VSV-based vaccination should be explored as a therapeutic strategy for cervical carcinoma and other HPV-associated cancers.